Trident Lifeline Ltd
Incorporated in 2014, Trident Lifeline Ltd manufactures and sells pharmaceuticals
products[1]
- Market Cap ₹ 353 Cr.
- Current Price ₹ 299
- High / Low ₹ 325 / 222
- Stock P/E 22.3
- Book Value ₹ 71.3
- Dividend Yield 0.00 %
- ROCE 27.6 %
- ROE 22.0 %
- Face Value ₹ 10.0
Pros
- Company is expected to give good quarter
- Company has delivered good profit growth of 78.5% CAGR over last 5 years
Cons
- Though the company is reporting repeated profits, it is not paying out dividend
- Promoter holding has decreased over last 3 years: -6.31%
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Peer comparison
Healthcare Healthcare Pharmaceuticals & Biotechnology Pharmaceuticals
Quarterly Results
Standalone Figures in Rs. Crores / View Consolidated
Profit & Loss
Standalone Figures in Rs. Crores / View Consolidated
| Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | TTM | |
|---|---|---|---|---|---|---|---|
| 5 | 10 | 22 | 32 | 45 | 68 | 84 | |
| 5 | 8 | 19 | 25 | 36 | 50 | 63 | |
| Operating Profit | -0 | 1 | 3 | 6 | 9 | 18 | 21 |
| OPM % | -5% | 13% | 12% | 20% | 20% | 26% | 25% |
| 0 | 0 | 1 | 1 | 2 | 3 | 4 | |
| Interest | 1 | 0 | 0 | 0 | 1 | 1 | 2 |
| Depreciation | 0 | 0 | 0 | 0 | 1 | 2 | 2 |
| Profit before tax | -1 | 1 | 3 | 7 | 10 | 18 | 21 |
| Tax % | -26% | 26% | -32% | 9% | 28% | 27% | |
| -1 | 1 | 4 | 6 | 7 | 13 | 16 | |
| EPS in Rs | -2.58 | 1.26 | 4.94 | 5.23 | 6.12 | 11.35 | 13.70 |
| Dividend Payout % | 0% | 0% | 0% | 0% | 0% | 0% |
| Compounded Sales Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | 69% |
| 3 Years: | 46% |
| TTM: | 48% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | 78% |
| 3 Years: | 49% |
| TTM: | 59% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | 32% |
| 1 Year: | 9% |
| Return on Equity | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | 20% |
| Last Year: | 22% |
Balance Sheet
Standalone Figures in Rs. Crores / View Consolidated
| Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Sep 2025 | |
|---|---|---|---|---|---|---|---|
| Equity Capital | 3 | 5 | 8 | 12 | 12 | 12 | 12 |
| Reserves | -6 | -5 | -3 | 34 | 41 | 54 | 71 |
| 6 | 5 | 2 | 3 | 6 | 15 | 21 | |
| 3 | 7 | 7 | 7 | 14 | 17 | 26 | |
| Total Liabilities | 6 | 11 | 14 | 56 | 73 | 98 | 129 |
| 1 | 1 | 1 | 3 | 8 | 15 | 17 | |
| CWIP | 0 | 0 | 0 | 0 | 4 | 1 | 1 |
| Investments | 0 | 0 | 0 | 4 | 4 | 12 | 15 |
| 6 | 10 | 12 | 49 | 57 | 70 | 97 | |
| Total Assets | 6 | 11 | 14 | 56 | 73 | 98 | 129 |
Cash Flows
Standalone Figures in Rs. Crores / View Consolidated
| Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|---|---|
| -1 | 1 | -0 | -17 | 1 | -3 | |
| -0 | -1 | -0 | -6 | -11 | -8 | |
| 1 | -1 | 1 | 36 | 2 | 7 | |
| Net Cash Flow | 0 | -0 | 0 | 14 | -8 | -4 |
Ratios
Standalone Figures in Rs. Crores / View Consolidated
| Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|---|---|
| Debtor Days | 97 | 24 | 83 | 140 | 112 | 110 |
| Inventory Days | 104 | 349 | 95 | 129 | 137 | 167 |
| Days Payable | 202 | 266 | 134 | 87 | 94 | 97 |
| Cash Conversion Cycle | -1 | 107 | 44 | 183 | 155 | 180 |
| Working Capital Days | -12 | 12 | 49 | 274 | 246 | 226 |
| ROCE % | 34% | 55% | 25% | 19% | 28% |
Documents
Announcements
-
Disclosures under Reg. 29(2) of SEBI (SAST) Regulations, 2011
2d - Acquisition of 10,800 shares on Dec 16, 2025 via warrant conversion; promoter stake cumulatively increased 0.85%.
-
Disclosures under Reg. 29(2) of SEBI (SAST) Regulations, 2011
2d - Hardik Desai Family Trust acquired 89,400 shares via warrant conversion on December 16, 2025 (preferential allotment).
-
Board Meeting Outcome for Outcome Of Board Meeting Held On Today I.E. On December 16, 2025, In Terms Of Second Proviso To Regulation 30(6) Of SEBI (LODR) Regulations, 2015
16 Dec - 100,200 shares allotted on warrant conversion; Rs.1,99,89,900 received; issued capital now Rs.11,79,80,000.
-
Announcement under Regulation 30 (LODR)-Allotment
16 Dec - Allotted 100,200 equity shares at Rs.266; received Rs.1,99,89,900; share capital now Rs.11,79,80,000.
-
Disclosures under Reg. 29(2) of SEBI (SAST) Regulations, 2011
10 Dec - Acquisition of 49,800 equity shares via warrant conversion on December 5, 2025; promoter stake rose to 6.33%
Annual reports
Concalls
-
Nov 2025TranscriptAI SummaryPPT
-
Jul 2025TranscriptAI SummaryPPT
-
Oct 2024TranscriptAI SummaryPPT
-
Jul 2024TranscriptAI SummaryPPT
-
May 2024TranscriptAI SummaryPPT
-
Nov 2023TranscriptAI SummaryPPT
-
Jul 2023TranscriptAI SummaryPPT
-
May 2023TranscriptAI SummaryPPT
-
Jan 2023TranscriptAI SummaryPPT
Business Overview:[1]
TFL is a pharmaceutical Company with business operations spanning formulations under its own brands, loan licence model and contract manufacturing model.
a) Pharmaceutical formulations export:
Company has a presence in 40 countries, including African, Latin America, and East
Asian countries, with ~945 registered export market products, and ~2016 export market products are under registration
b) Contract manufacturing:
Company follows an Asset-light third-party contract manufacturing model thus entailing limited direct investment in manufacturing capacities